Aurinia Pharmaceuticals Stock Performance
| AUPH Stock | USD 9.12 0.14 1.56% |
On a scale of 0 to 100, Aurinia Pharmaceuticals holds a performance score of 9. The firm shows a Beta (market volatility) of 0.81, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aurinia Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aurinia Pharmaceuticals is expected to be smaller as well. Please check Aurinia Pharmaceuticals' treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Aurinia Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Aurinia Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Aurinia Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.34 | Five Day Return 0.34 | Year To Date Return 2.75 | Ten Year Return 146.03 | All Time Return 130.26 |
Last Split Factor 1:50 | Last Split Date 2013-10-23 |
1 | Disposition of 4650 shares by Billen Daniel of Aurinia Pharmaceuticals at 11.26 subject to Rule 16b-3 | 10/21/2024 |
2 | Disposition of 8733 shares by Jayne David R.w. of Aurinia Pharmaceuticals subject to Rule 16b-3 | 10/25/2024 |
3 | Earnings call Aurinia Pharmaceuticals announced a 24 percent increase in total net revenue | 11/07/2024 |
4 | Disposition of 5241 shares by Smith Karen L. of Aurinia Pharmaceuticals at 8.43 subject to Rule 16b-3 | 11/11/2024 |
5 | Aurinia Pharmaceuticals director Karen Smith sells 44,181 in stock | 11/13/2024 |
6 | Aurinia to Participate in Jefferies London Healthcare Conference | 11/14/2024 |
7 | Acquisition by Jayne David R.w. of 18641 shares of Aurinia Pharmaceuticals at 8.24 subject to Rule 16b-3 | 11/21/2024 |
8 | Disposition of 25146 shares by Knappertz Volker of Aurinia Pharmaceuticals at 5.48 subject to Rule 16b-3 | 11/29/2024 |
9 | Acquisition by Tang Kevin of 300000 shares of Aurinia Pharmaceuticals at 8.91 subject to Rule 16b-3 | 12/05/2024 |
10 | Acquisition by Tang Kevin of 500000 shares of Aurinia Pharmaceuticals at 9.09 subject to Rule 16b-3 | 12/09/2024 |
11 | Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options | 12/10/2024 |
12 | Sunbelt Securities Inc. Cuts Stock Holdings in Aurinia Pharmaceuticals Inc. | 12/12/2024 |
13 | Aurinia Pharmaceuticals laying off dozens in Montgomery County | 12/24/2024 |
| Begin Period Cash Flow | 94.2 M |
Aurinia |
Aurinia Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 728.00 in Aurinia Pharmaceuticals on September 27, 2024 and sell it today you would earn a total of 170.00 from holding Aurinia Pharmaceuticals or generate 23.35% return on investment over 90 days. Aurinia Pharmaceuticals is currently generating 0.3773% in daily expected returns and assumes 3.041% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Aurinia, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aurinia Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aurinia Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aurinia Pharmaceuticals, and traders can use it to determine the average amount a Aurinia Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1241
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AUPH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.04 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.38 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Aurinia Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aurinia Pharmaceuticals by adding it to a well-diversified portfolio.
Aurinia Pharmaceuticals Fundamentals Growth
Aurinia Stock prices reflect investors' perceptions of the future prospects and financial health of Aurinia Pharmaceuticals, and Aurinia Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aurinia Stock performance.
| Return On Equity | -0.0578 | ||||
| Return On Asset | -0.0216 | ||||
| Profit Margin | (0.10) % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 143.18 M | ||||
| Price To Earning | (4.83) X | ||||
| Price To Book | 3.31 X | ||||
| Price To Sales | 5.83 X | ||||
| Revenue | 175.51 M | ||||
| Gross Profit | 83.38 M | ||||
| EBITDA | (63.05 M) | ||||
| Net Income | (78.02 M) | ||||
| Cash And Equivalents | 391.51 M | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 97.61 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 13.09 X | ||||
| Book Value Per Share | 2.71 X | ||||
| Cash Flow From Operations | (33.46 M) | ||||
| Earnings Per Share | (0.15) X | ||||
| Market Capitalization | 1.29 B | ||||
| Total Asset | 548.06 M | ||||
| Retained Earnings | (942.32 M) | ||||
| Working Capital | 347.61 M | ||||
| Current Asset | 16.53 M | ||||
| Current Liabilities | 3.62 M | ||||
About Aurinia Pharmaceuticals Performance
By evaluating Aurinia Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Aurinia Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aurinia Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aurinia Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1 K | 1.1 K | |
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.19) | (0.20) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | (0.21) | (0.22) |
Things to note about Aurinia Pharmaceuticals performance evaluation
Checking the ongoing alerts about Aurinia Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aurinia Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aurinia Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 175.51 M. Net Loss for the year was (78.02 M) with profit before overhead, payroll, taxes, and interest of 83.38 M. | |
| Aurinia Pharmaceuticals currently holds about 391.51 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Aurinia Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from bizjournals.com: Aurinia Pharmaceuticals laying off dozens in Montgomery County |
- Analyzing Aurinia Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aurinia Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Aurinia Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aurinia Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aurinia Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aurinia Pharmaceuticals' stock. These opinions can provide insight into Aurinia Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |